US 12,186,393 B2
Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation
Benjamin Lewis, Palo Alto, CA (US); Christina Kelly Lopes, Palo Alto, CA (US); Lindsay Lambert, Palo Alto, CA (US); Garrett Harvey, Palo Alto, CA (US); Thaddeus A. Allen, Palo Alto, CA (US); Aubrey Miller, Palo Alto, CA (US); Lucas Rodrigues, Palo Alto, CA (US); Madison Luker, Palo Alto, CA (US); and Gerald Post, Palo Alto, CA (US)
Assigned to ONEHEALTHCOMPANY, INC., Palo Alto, CA (US)
Appl. No. 17/632,327
Filed by ONEHEALTHCOMPANY, INC., Palo Alto, CA (US)
PCT Filed Aug. 2, 2020, PCT No. PCT/US2020/044689
§ 371(c)(1), (2) Date Feb. 2, 2022,
PCT Pub. No. WO2021/026046, PCT Pub. Date Feb. 11, 2021.
Claims priority of provisional application 62/909,098, filed on Oct. 1, 2019.
Claims priority of provisional application 62/906,924, filed on Sep. 27, 2019.
Claims priority of provisional application 62/904,987, filed on Sep. 24, 2019.
Claims priority of provisional application 62/902,889, filed on Sep. 19, 2019.
Claims priority of provisional application 62/901,185, filed on Sep. 16, 2019.
Claims priority of provisional application 62/899,932, filed on Sep. 13, 2019.
Claims priority of provisional application 62/898,888, filed on Sep. 11, 2019.
Claims priority of provisional application 62/897,872, filed on Sep. 9, 2019.
Claims priority of provisional application 62/882,401, filed on Aug. 2, 2019.
Prior Publication US 2022/0354951 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 41/00 (2020.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61K 31/517 (2006.01); A61K 39/00 (2006.01)
CPC A61K 41/00 (2013.01) [A61K 31/519 (2013.01); A61P 35/02 (2018.01); A61K 31/517 (2013.01); A61K 2039/505 (2013.01); A61P 35/00 (2018.01)] 20 Claims
 
1. A method of treating transitional cell carcinoma in a canine subject, comprising: administering to the canine subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising Lapatinib, wherein the transitional cell carcinoma harbors at least one mutation in BRAF.